 MENLO PARK, Calif., July 14, 2021 GLOBE NEWSWIRE -- CohBar, Inc. NASDAQ: CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced an update on the timing for the release of the data for its Phase 1a1b clinical study of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity. The process of data entry and final validation by the companys clinical research organization, which must be concluded prior to database lock, is ongoing. Once the database is locked, external biostatisticians will have access to the unblinded data from the study, enabling them to perform the data analysis and generate the final output. Only after this process is complete will the data be provided to the company. The company currently expects to release topline data prior to Labor Day 2021. 